Intercure Ltd. Ordinary Shares (INCR)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

InterCure is a small medical-cannabis producer and distributor with 285 employees, selling dried flower and oil-based extracts. In Graham terms, I start with financial strength. The given data is not encouraging: the stock closed at $5.03 on 2026-10-13, with a market cap of $48.1M. The FairStock calculations show a negative P/E of -4.61 and a P/B of 0.66, so there are no earnings to value but the shares trade below stated book value. FairStock-calculated ROE is -9.27% and ROCE is -5.78%. A Piotroski F-Score of 1/9 and an Altman Z-Score of -0.36 point to a fragile balance sheet, even though debt-to-equity of 0.46 is not extreme. The FairStock Score of 44/100 is middling at best. The one apparent attraction is P/B of 0.66, meaning the shares trade at a discount to book value. But a discount to book is only a margin of safety if the book value is real and the business can earn a return. Here, with losses, the book value may be at risk. The Lynch category is none because there are only 0 years of filed results and the rule needs 3; revenue and profit growth are unavailable. That lack of history makes growth impossible to judge. Beta of 0.59 suggests lower price volatility, and the 52-week range of $0.68 to $6.10 shows sharp swings. As a Buffett-style investor, I need durable competitive advantage, consistent earning power, and honest long-term numbers. The figures show none of those yet. The price looks statistically cheap, but the business quality is weak. I would wait for filed evidence of profitability and a sturdier balance sheet before treating this as a value opportunity.

In plain English: InterCure makes and sells medical cannabis products, mainly in Israel and other countries. The business looks weak right now because it is losing money and has low financial-strength scores. The stock looks cheap compared with the accounting value of its assets minus debts, but that cheapness comes with high risk since profits are negative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer